Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)

View Full Paper
Ask AI
Bookmark
Share

Authors

SGSimon Le GallouDRDelphine RossilleACAlexis Claudel

Discussion

Loading...

Member takes

Overview

Observational findings linked leukapheresis immune profiles to progression risk in large B-cell lymphoma, highlighting biomarkers for patient stratification.

Key Points

  • To identify immune cell signatures that predict progression-free survival and complete metabolic response in large B-cell lymphoma after CAR T-cell therapy.
  • Analyzed blood samples prospectively collected during the ALYCANTE trial.
  • Characterized immune cell subsets via high-dimensional mass cytometry (CyTOF).
  • Evaluated 40 R/R LBCL patients' leukapheresis profiles for associations with outcomes.
  • CMR3 achieved in 62.5% of patients over 27 analyzed.
  • Increased counts of specific immune cells correlated with lower progression-free survival events.
  • In multivariable analysis, increased T15 levels associated with reduced PFS12 risk.

Cite This Study

Gallou et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dafahttps://doi.org/10.1182/blood-2025-5332
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma2025
  2. 2Prognostic impact of CAR-T cell expansion and PD1 expression in patients with DLBCL treated with axicabtagene ciloleucel2025
  3. 3Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy2025
  4. 4Monocytes in leukapheresis products affect the outcome of CD19–targeted CAR T-cell therapy in patients with lymphoma2024 · 27 citations
  5. 5Lymphocyte kinetics as a predictor of clinical outcomes following CAR-T therapy for non-Hodgkin lymphoma2025